Download PDF
Horm Metab Res 2024; 56(02): 150-158
DOI: 10.1055/a-2180-6624
Original Article: Endocrine Research

LINC00092 Enhances LPP Expression to Repress Thyroid Cancer Development via Sponging miR-542-3p

Huan Wang
1   General Practice Section, Wuhan University of Science and Technology Hospital, Wuhan, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

LINC00092 is poorly expressed in Thyroid cancer (TC), while its role in TC tumorigenesis is still elusive. This study aimed to reveal the role and regulatory mechanism of LINC00092 in TC.

RNA immunoprecipitation and dual luciferase reporter assays were employed to ascertain the relationships among lipoma preferred partner (LPP), miR-542-3p, and LINC00092. qRT-PCR analysis was performed to detect their expression levels in TC. LPP protein productions were evaluated via western blotting. CCK-8, transwell, and colony formation assays were done to estimate TC cells’ biological functions. A murine xenograft model was built to observe tumor formation in vivo.

LINC00092 overexpression decreased the expression levels of miR-542-3p, and LPP was targeted by miR-542-3p. In TC cells and tissues, the elevation of miR-542-3p, and low amounts of LINC00092 and LPP can be observed. Both LINC00092 and SPAG6 were considered as the antineoplastic factors in TC since their overexpression dramatically repressed TC cells’ invasive and proliferative potentials, while miR-542-3p exerted the opposite functions in TC. The ectopic expression of LINC00092 also suppressed tumor growth in vivo. In addition, it revealed that miR-542-3p upregulation reversed LINC00092 overexpression-mediated effects on TC cells. At the same time, the enhanced influences of TC cells caused by miR-542-3p upregulation could be attenuated by the enforced LPP.

This study innovatively reveals that LINC00092 acts as an antineoplastic lncRNA to restrain the development of TC via regulating miR-542-3p/LPP. The findings of this study may provide a prospective drug target on LINC00092/miR-542-3p/LPP axis for the treatment of TC.

Key words

thyroid cancer - lncRNA - LINC00092 - miR-542-3p - LPP


Publication History

Received: 13 April 2023

Accepted after revision: 14 September 2023

Article published online:
07 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Huang Y, Prasad M, Lemon WJ. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001; 98: 15044-15049
    CrossrefPubMedSearch in Google Scholar
  • 2 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010; 22: 395-404
    CrossrefPubMedSearch in Google Scholar
  • 3 Mahmoudian-Sani MR, Jalali A, Jamshidi M. et al. Long non-coding RNAs in thyroid cancer: implications for pathogenesis, diagnosis, and therapy. Oncol Res Treat 2019; 42: 136-142
    CrossrefPubMedSearch in Google Scholar
  • 4 Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016; 375: 2307
    CrossrefPubMedSearch in Google Scholar
  • 5 Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 2016; 23: 313-322
    CrossrefPubMedSearch in Google Scholar
  • 6 Kreissl MC, Janssen MJR, Nagarajah J. Current treatment strategies in metastasized differentiated thyroid cancer. J Nucl Med 2019; 60: 9-15
    CrossrefPubMedSearch in Google Scholar
  • 7 Filetti S, Durante C, Hartl D. et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1856-1883
    CrossrefPubMedSearch in Google Scholar
  • 8 Lu W, Xu Y, Xu J. et al. Identification of differential expressed lncRNAs in human thyroid cancer by a genome-wide analyses. Cancer Med 2018; 7: 3935-3944
    CrossrefPubMedSearch in Google Scholar
  • 9 Zhao H, De Souza C, Kumar VE. et al. Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review. Ann Transl Med 2021; 9: 359
    CrossrefPubMedSearch in Google Scholar
  • 10 Ghafouri-Fard S, Mohammad-Rahimi H, Taheri M. The role of long non-coding RNAs in the pathogenesis of thyroid cancer. Exp Mol Pathol 2020; 112: 104332
    CrossrefPubMedSearch in Google Scholar
  • 11 Liu L, Yang J, Zhu X. et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J 2016; 283: 2326-2339
    CrossrefPubMedSearch in Google Scholar
  • 12 Fu XD, Liu CY, Liu YL. et al. LINC00261 regulates EBF1 to suppress malignant progression of thyroid cancer. Eur Rev Med Pharmacol Sci 2021; 25: 7626-7634
    PubMedSearch in Google Scholar
  • 13 Jia M, Li Z, Pan M. et al. LINC-PINT suppresses the aggressiveness of thyroid cancer by downregulating miR-767-5p to induce TET2 expression. Mol Ther Nucleic Acids 2020; 22: 319-328
    CrossrefPubMedSearch in Google Scholar
  • 14 Zhao L, Ji G, Le X. et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res 2017; 77: 1369-1382
    CrossrefPubMedSearch in Google Scholar
  • 15 Wang X, Wang X, Huang G. et al. Lower expression of LINC00092 in lung adenocarcinoma might mean poorer prognosis: A study based on data mining and bioinformatics. Medicine (Baltimore) 2020; 99: e23012
    CrossrefPubMedSearch in Google Scholar
  • 16 Zhang Y, Jin T, Shen H. et al. Identification of long non-coding RNA expression profiles and co-expression genes in thyroid carcinoma based on the cancer genome atlas (TCGA) database. Med Sci Monit 2019; 25: 9752-9769
    CrossrefPubMedSearch in Google Scholar
  • 17 Chen Y, Gao H, Li Y. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-·1/Smads signaling pathway. Mol Cell Endocrinol 2020; 500: 110634
    CrossrefPubMedSearch in Google Scholar
  • 18 Zhang X, Zhang X, Jia Q. et al. LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis. BMC Cancer 2022; 22: 344
    CrossrefPubMedSearch in Google Scholar
  • 19 Althoff K, Lindner S, Odersky A. et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer 2015; 136: 1308-1320
    CrossrefPubMedSearch in Google Scholar
  • 20 Liu B, Li J, Zheng M. et al. MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2. Life Sci 2017; 188: 87-95
    CrossrefPubMedSearch in Google Scholar
  • 21 Zhang T, Liu W, Meng W. et al. Downregulation of miR-542-3p promotes cancer metastasis through activating TGF-β/Smad signaling in hepatocellular carcinoma. Onco Targets Ther 2018; 11: 1929-1939
    CrossrefPubMedSearch in Google Scholar
  • 22 Yuan L, Yuan P, Yuan H. et al. miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1. Am J Cancer Res 2017; 7: 159-172
    PubMedSearch in Google Scholar
  • 23 Wu HX, Wang GM, Lu X. et al. miR-542-3p targets sphingosine-1-phosphate receptor 1 and regulates cell proliferation and invasion of breast cancer cells. Eur Rev Med Pharmacol Sci 2017; 21: 108-114
    PubMedSearch in Google Scholar
  • 24 Li J, Shao W, Feng H. MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. Biomed Pharmacother 2019; 110: 850-856
    CrossrefPubMedSearch in Google Scholar
  • 25 Peng G, Guan J, Leng P. et al. Circular RNA circ_0000515 adsorbs miR-542-3p to accelerate bladder cancer progression via up-regulating ILK expression. Aging (Albany NY) 2022; 14: 430-442
    CrossrefPubMedSearch in Google Scholar
  • 26 Petit MM, Mols R, Schoenmakers EF. et al. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 1996; 36: 118-129
    CrossrefPubMedSearch in Google Scholar
  • 27 Grunewald TG, Pasedag SM, Butt E. Cell Adhesion and transcriptional activity - defining the role of the novel protooncogene LPP. Transl Oncol 2009; 2: 107-116
    CrossrefPubMedSearch in Google Scholar
  • 28 Yang Y, Wang D, Tao K. et al. Circular RNA circLRCH3 inhibits proliferation, migration, and invasion of colorectal cancer cells through miRNA-223/LPP axis. Onco Targets Ther 2022; 15: 541-554
    CrossrefPubMedSearch in Google Scholar
  • 29 Kuriyama S, Yoshida M, Yano S. et al. LPP inhibits collective cell migration during lung cancer dissemination. Oncogene 2016; 35: 952-964
    CrossrefPubMedSearch in Google Scholar
  • 30 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29
    CrossrefPubMedSearch in Google Scholar
  • 31 Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017; 235: R43-R61
    CrossrefPubMedSearch in Google Scholar
  • 32 Erol V, Makay Ö, İçöz G. et al. The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer. Ulus Cerrahi Derg 2013; 29: 7-10
    PubMedSearch in Google Scholar
  • 33 Guo K, Qian K, Shi Y. et al. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis 2021; 12: 1097
    CrossrefPubMedSearch in Google Scholar
  • 34 Liu H, Deng H, Zhao Y. et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res 2018; 37: 279
    CrossrefPubMedSearch in Google Scholar
  • 35 Yuan J, Song Y, Pan W. et al. LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5. Oncogene 2020; 39: 6664-6676
    CrossrefPubMedSearch in Google Scholar
  • 36 Zhao CM, Li LL, Xu JW. et al. LINC00092 suppresses the malignant progression of breast invasive ductal carcinoma through modulating SFRP1 expression by sponging miR-1827. Cell Transplant 2022; 31: 9636897221086967
    CrossrefPubMedSearch in Google Scholar
  • 37 Si C, Yu Q, Yao Y. Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5. Exp Ther Med 2018; 15: 4515-4521
    PubMedSearch in Google Scholar
  • 38 Liu X, Liu B, Li R. et al. miR-146a-5p Plays an oncogenic role in NSCLC via suppression of TRAF6. Front Cell Dev Biol 2020; 8: 847
    CrossrefPubMedSearch in Google Scholar
  • 39 Chen C, Zhang Z, Li J. et al. SNHG8 is identified as a key regulator in non-small-cell lung cancer progression sponging to miR-542-3p by targeting CCND1/CDK6. Onco Targets Ther 2018; 11: 6081-6090
    CrossrefPubMedSearch in Google Scholar
  • 40 Liu Q, Zhang W, Luo L. et al. Long noncoding RNA TUG1 regulates the progression of colorectal cancer through miR-542-3p/TRIB2 axis and Wnt/·-catenin pathway. Diagn Pathol 2021; 16: 47
    CrossrefPubMedSearch in Google Scholar
  • 41 Li Q, Liu W, Li S. et al. Long non-coding RNA CASC15 favors tumorigenesis and development of ovarian cancer via sponging miR-542-3p. Panminerva Med 2021; 63: 245-246
    PubMedSearch in Google Scholar